1 in 3 Bharat Biotech Covaxin takers reported adverse events, finds BHU study
In light of growing concerns about COVID-19 vaccine safety, a comprehensive one-year follow-up study by Banaras Hindu University (BHU) researchers sheds light on the long-term effects of Bharat Biotech's Covaxin. This study aimed to assess adverse events of special interest (AESI) among vaccine recipients, providing crucial insights into the vaccine's safety profile.
The study included 635 adolescents and 291 adults, revealing that nearly one-third of the participants reported AESI. Among adolescents, common AESIs included new-onset skin and subcutaneous disorders (10.5%), general disorders (10.2%), and nervous system disorders (4.7%). In adults, the prevalent AESIs were general disorders (8.9%), musculoskeletal disorders (5.8%), and nervous system disorders (5.5%). Serious AESIs, such as stroke and Guillain-Barre syndrome, were reported in 1% of participants.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd